Drug Profile
Lithium succinate
Alternative Names: Efadermin; EfalithLatest Information Update: 24 Sep 2015
Price :
$50
*
At a glance
- Originator Louis Widmer; Scotia Holdings [CEASED]
- Class Small molecules; Succinates
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Seborrhoeic dermatitis
- Discontinued Atopic dermatitis; Human papillomavirus infections; Mycoses
Most Recent Events
- 02 Apr 2015 The product is approved for Seborrhoeic dermatitis in EU countries and South Africa
- 26 Jan 2012 Withdrawn for Seborrhoeic dermatitis in Ireland (Topical)
- 22 Jan 2002 No-Development-Reported for Human papillomavirus infections in United Kingdom (Topical)